VCISY yields 3.61% · PFE yields 6.13%● Live data
📍 VCISY pulled ahead of the other in Year 1
Combined, VCISY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VCISY + PFE for your $10,000?
VINCI SA, together with its subsidiaries, operates in the concessions, energy, and construction segments primarily in France. It Concessions segment operates motorway concessions with a network of 4,419 kilometers in France; 45 airports; 4,437 kilometers of motorways; highways, railways, and 4 stadiums, as well as operates airports in France and in 11 other countries. The company's Energy segment provides services to the manufacturing, infrastructure, facilities management, and information and communication technology sectors; engineering, procurement, and construction services in the energy sector, and manufacturing and energy-related services; and renewable energy concession projects development services. Its Construction segments engages in designing and carrying out projects that involve general contractor capabilities; works related to geotechnical and structural engineering, digital technology, nuclear or renewable thermal energy; and focuses on business area, such as buildings, civil engineering, infrastructure, and in a specific geographical area. The company also provides property development services for residential and commercial properties; and property services, as well as operates managed residences. It also operates in Germany, the United Kingdom, Albania, Belarus, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Kosovo, Latvia, Lithuania, Macedonia, Moldova, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Ukraine, Portugal, North America, Central and South America, Africa, Russia, the Asia-Pacific, the Middle East, and other European countries. The company was founded in 1899 and is headquartered in Nanterre, France.
Full VCISY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.